Advertisement

United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic

Published:April 16, 2020DOI:https://doi.org/10.1016/j.jaad.2020.04.049
      Evidence suggests that patients with malignancy
      • Liang W.
      • Guan W.
      • Chen R.
      • et al.
      Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
      and older age have a higher risk of severe events including death
      • Yang J.
      • Zheng Y.
      • Gou X.
      • et al.
      Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis.
      ,
      • Wang T.
      • Du Z.
      • Zhu F.
      • et al.
      Comorbidities and multi-organ injuries in the treatment of COVID-19.
      due to COVID-19.
      • Wu Z.
      • McGoogan J.M.
      Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.
      Patients with primary cutaneous lymphoma tend to be older and to receive immunosuppressive therapy long term for disease control. Because both the cutaneous lymphoma and the type of immunosuppressive treatment can contribute to the development of more severe complications from COVID-19, we propose strategies for treating patients with primary cutaneous lymphomas by dividing both into low-, intermediate-, and high-risk categories (see recommendations for individual therapies in Supplemental Table I; available via Mendeley at doi:10.17632/7f3jvhw74s.1).

      Key words

      Abbreviations used:

      MF (mycosis fungoides), PC (primary cutaneous), UV (ultraviolet)
      To read this article in full you will need to make a payment
      AAD Member Login
      AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Liang W.
        • Guan W.
        • Chen R.
        • et al.
        Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.
        Lancet Oncol. 2020; 21: 335-337
        • Yang J.
        • Zheng Y.
        • Gou X.
        • et al.
        Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis.
        Int J Infect Dis. 2020; ([e-pub ahead of print])https://doi.org/10.1016/j.ijid.2020.03.017
        • Wang T.
        • Du Z.
        • Zhu F.
        • et al.
        Comorbidities and multi-organ injuries in the treatment of COVID-19.
        Lancet. 2020; 395: e52
        • Wu Z.
        • McGoogan J.M.
        Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention.
        JAMA. 2020; ([e-pub ahead of print])https://doi.org/10.1001/jama.2020.2648